Skip to content

Study · Randomized controlled trial · n = 79 · 2026

4 results

Sodium depletion is associated with the response to glepaglutide in short bowel syndrome with chronic intestinal failure.

Foerster RH, Nielsen TSS, Santacruz BG, Berner-Hansen M, Lamprecht G

Clinical nutrition ESPEN24 Oct 2026

PMID42926062 (opens in a new tab)DOI10.1016/j.clnesp.2026.105211 (opens in a new tab)PepBankPUB-42926062
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In SBS-CIF patients without sodium depletion, glepaglutide reduced parenteral support more than placebo (p = 0.02).

    In plain wordsIn SBS-CIF patients without sodium depletion, glepaglutide reduced parenteral support more than placebo.

    Peptide
    Glepaglutide
    Outcome
    DecreaseParenteral support volume reduction without baseline sodium depletion
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    10 mg once or twice weekly · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients without sodium depletion (n = 79) had a significantly greater PS reduction with glepaglutide vs. placebo (p = 0.02).
    2 context sentences
    Summary · context
    The phase 3a EASE SBS-1 trial randomized 106 SBS patients with CIF (type III, according to the ESPEN classification) to receive glepaglutide 10 mg once (OW) or twice weekly (TW) vs. placebo for 24 weeks.
    Summary · context
    Groups receiving glepaglutide OW or TW were pooled in all analyses.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In nondepleted SBS-CIF patients, clinical response was numerically more likely with glepaglutide than placebo, without statistical significance (p = 0.12).

    In plain wordsIn nondepleted SBS-CIF patients, clinical response was numerically more likely with glepaglutide than placebo, but the difference was not significant.

    Peptide
    Glepaglutide
    Outcome
    No significant changeClinical response without baseline sodium depletion
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    10 mg once or twice weekly · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The nondepleted patients receiving glepaglutide were numerically more likely to achieve a clinical response in PS reduction (p = 0.12).
    3 context sentences
    Summary · context
    Patients without sodium depletion (n = 79) had a significantly greater PS reduction with glepaglutide vs. placebo (p = 0.02).
    Summary · context
    The phase 3a EASE SBS-1 trial randomized 106 SBS patients with CIF (type III, according to the ESPEN classification) to receive glepaglutide 10 mg once (OW) or twice weekly (TW) vs. placebo for 24 weeks.
    Summary · context
    Groups receiving glepaglutide OW or TW were pooled in all analyses.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In SBS-CIF patients with baseline sodium depletion, parenteral support reduction did not differ significantly between glepaglutide and placebo.

    In plain wordsIn SBS-CIF patients with sodium depletion, parenteral support reduction did not differ significantly between glepaglutide and placebo.

    Peptide
    Glepaglutide
    Outcome
    No significant changeParenteral support volume reduction with baseline sodium depletion
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    10 mg once or twice weekly · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients with sodium depletion at baseline had nonsignificant differences in PS reduction or clinical response (n = 27)
    2 context sentences
    Summary · context
    The phase 3a EASE SBS-1 trial randomized 106 SBS patients with CIF (type III, according to the ESPEN classification) to receive glepaglutide 10 mg once (OW) or twice weekly (TW) vs. placebo for 24 weeks.
    Summary · context
    Groups receiving glepaglutide OW or TW were pooled in all analyses.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In SBS-CIF patients with baseline sodium depletion, clinical response did not differ significantly between glepaglutide and placebo.

    In plain wordsIn SBS-CIF patients with sodium depletion, clinical response did not differ significantly between glepaglutide and placebo.

    Peptide
    Glepaglutide
    Outcome
    No significant changeClinical response with baseline sodium depletion
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    10 mg once or twice weekly · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients with sodium depletion at baseline had nonsignificant differences in PS reduction or clinical response (n = 27)
    2 context sentences
    Summary · context
    The phase 3a EASE SBS-1 trial randomized 106 SBS patients with CIF (type III, according to the ESPEN classification) to receive glepaglutide 10 mg once (OW) or twice weekly (TW) vs. placebo for 24 weeks.
    Summary · context
    Groups receiving glepaglutide OW or TW were pooled in all analyses.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.